MiR-21 increases the programmed cell death 4 gene-regulated cell proliferation in head and neck squamous carcinoma cell lines

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2283-2289

  Sun, Zhifeng ^a,b   Li, Suping ^b   Kaufmann, Andreas M ^a   Albers, Andreas E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Affiliated Hospital of Hubei Nationalities University   (China)

Author keywords

Dormancy; Head and neck squamous cell carcinoma; MiR 21; Programmed cell death 4

Indexed keywords

MICRORNA; MICRORNA 138 1; MICRORNA 138 2; MICRORNA 200C; MICRORNA 21; MICRORNA 25; MICRORNA 34; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; APOPTOSIS REGULATORY PROTEIN; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MTT ASSAY; ONCOGENE; PDCD4 GENE; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; UPREGULATION; WESTERN BLOTTING; BIOLOGY; CELL CYCLE; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; RNA-BINDING PROTEINS;

EID: 84907291841     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3456     Document Type: Article

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Cheng ZX, Sun B, Wang SJ, et al: Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. PLoS One 6: e23752, 2011.
3. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8 (Suppl 4): S62-S67, 2002.
4. Imai T, Horiuchi A, Wang C, et al: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163: 1437-1447, 2003.
5. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
6. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
7. Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462-469, 2008.
8. Chu Y, Zhu H, Lv L, Zhou Y and Huo J: MiRNAs in oesophageal squamous cancer. Neth J Med 71: 69-75, 2013.
9. Janiszewska J, Szaumkessel M and Szyfter K: microRNAs are important players in head and neck carcinoma: a review. Crit Rev Oncol Hematol 88: 716-728, 2013.
10. Wu Q, Wang C, Lu Z, Guo L and Ge Q: Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 413: 1058-1065, 2012.
11. Liang H, Gong F, Zhang S, Zhang CY, Zen K and Chen X: The origin, function, and diagnostic potential of extracellular microRNAs in human body fluids. Wiley Interdiscip Rev RNA 5: 285-300, 2014.
12. Endo K, Weng H, Kito N, Fukushima Y and Iwai N: miR-216a and miR-216b as markers for acute phased pancreatic injury. Biomed Res 34: 179-188, 2013.
13. Olivieri F, Rippo MR, Procopio AD and Fazioli F: Circulating inflamma-miRs in aging and age-related diseases. Front Genet 4: 121, 2013.
14. de Yébenes VG, Bartolomé-Izquierdo N and Ramiro AR: Regulation of B-cell development and function by microRNAs. Immunol Rev 253: 25-39, 2013.
15. Stefani G: Roles of microRNAs and their targets in cancer. Expert Opin Biol Ther 7: 1833-1840, 2007.
16. Yang J, Hao Y and Xi JJ: Therapeutic application of microRNAs against human cancers. J Lab Autom 18: 30-33, 2013.
17. Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol 223: 102-115, 2011.
18. Lo WL, Yu CC, Chiou GY, et al: MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol 223: 482-495, 2011.
19. Liu X, Jiang L, Wang A, Yu J, Shi F and Zhou X: MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett 286: 217-222, 2009.
20. Chen HC, Chen GH, Chen YH, et al: MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 100: 1002-1011, 2009.
21. Xu X, Chen Z, Zhao X, et al: MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 421: 640-645, 2012.
22. Gao W, Xu J, Liu L, Shen H, Zeng H and Shu Y: A systematicanalysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother 66: 21-28, 2012.
23. Schee K, Boye K, Abrahamsen TW, Fodstad O and Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12: 505, 2012.
24. Young MR, Santhanam AN, Yoshikawa N and Colburn NH: Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue? Mol Interv 10: 76-79, 2010.
25. Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73: 185-191, 2010.
26. Fassan M, Pizzi M, Battaglia G, et al: Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol 63: 692-696, 2010.
27. Fassan M, Pizzi M, Giacomelli L, et al: PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch 458: 413-419, 2011.
28. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
29. Wolf JS, Chen Z, Dong G, et al: IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7: 1812-1820, 2001.
30. Itani S, Kunisada T, Morimoto Y, et al: MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4). J Cancer Res Clin Oncol 138: 1501-1509, 2012.
31. Horiuchi A, Iinuma H, Akahane T, Shimada R and Watanabe T: Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients. Oncol Rep 27: 1384-1392, 2012.
32. Wang J and Zhang Y: Expression of programmed cell death 4 protein is closely correlated with laryngeal squamous cell carcinomas. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 25: 539-541, 2011 (In Chinese).
33. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
34. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
35. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005.
36. Shi GH, Ye DW, Yao XD, et al: Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 31: 867-873, 2010.
37. Xu YZ, Xi QH, Ge WL and Zhang XQ: Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev 14: 1057-1060, 2013.
38. Giovannetti E, Funel N, Peters GJ, et al: MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538, 2010.
39. Feng YH, Wu CL, Tsao CJ, et al: Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: correlation with the clinical stage of the disease. Cancer Biol Ther 11: 111-121, 2011.
40. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY and Yan M: microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep 27: 1019-1026, 2012.
41. Selaru FM, Olaru AV, Kan T, et al: MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49: 1595-1601, 2009.
42. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
43. Tran N, McLean T, Zhang X, et al: MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 358: 12-17, 2007.
44. Huang S, Li XQ, Chen X, Che SM, Chen W and Zhang XZ: Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Dis Esophagus 26: 823-831, 2013.
45. Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436, 2008.
46. Dillhoff M, Liu J, Frankel W, Croce C and Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12: 2171-2176, 2008.
47. Asangani IA, Rasheed SA, Nikolova DA, et al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136, 2008.
48. Feber A, Xi L, Luketich JD, et al: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 135: 255-260, 2008.
49. Fulci V, Chiaretti S, Goldoni M, et al: Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109: 4944-4951, 2007.
50. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007.
51. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704, 2008.
52. Yang HS, Jansen AP, Nair R, et al: A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation. Oncogene 20: 669-676, 2001.
53. Jansen AP, Camalier CE, Stark C and Colburn NH: Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 3: 103-110, 2004.
54. Jansen AP, Camalier CE and Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 65: 6034-6041, 2005.
55. Göke A, Göke R, Knolle A, et al: DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem Biophys Res Commun 297: 78-82, 2002.
56. Yang HS, Jansen AP, Komar AA, et al: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23: 26-37, 2003.
57. WAF1/CIP1. Am J Physiol Cell Physiol 287: C1541-C1546, 2004.
58. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033, 2008.
59. Xu L, Dai WQ, Xu XF, Wang F, He L and Guo CY: Effects of multiple-target anti-microRNA antisense oligodeoxyribonucleotides on proliferation and migration of gastric cancer cells. Asian Pac J Cancer Prev 13: 3203-3207, 2012.
60. Lennox KA and Behlke MA: A direct comparison of antimicroRNA oligonucleotide potency. Pharm Res 27: 1788-1799, 2010.